CRSP:NASDAQ
Crispr Therapeutics AG
$48.41
arrow_downward
-4.04%(-2.04) 1D
$48.64
arrow_upward
+0.46% (+0.22)bedtimeAfter hours
Closed: May 15, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
$49.74
High
$50.45
Low
$48.25
Mkt. cap
4.67B
Avg. vol.
1.72M
Volume
1.98M
52-wk high
$78.48
52-wk low
$35.38
EPS
-$6.21
Beta
1.27
Shares outstanding
96.45M
No. of employees
393
News stories
From sources across the web
Simply Wall Street
·
22 hours ago
Is CRISPR (CRSP) Quietly Rewriting Its Gene‑Editing Priorities After Narrower Losses and Casgevy Progress?
Stock Titan
·
3 days ago
Capital World Investors discloses 5.1% stake in CRSP (4.93M shares)
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitecrisprtx.com
AI content may include mistakes. Learn more